Susan Morris

The main focus of my research is to generate Simian adenoviral vectored vaccines for a range of emerging and re-emerging pathogens including SARS CoV-2. Emerging pathogen outbreaks require a quick and efficient response. Manufacturing methods for Adenovirus vectors at large scale have been developed, however the process from selecting an antigen to starting a clinical trial takes at least 18 months, which has ruled out the current manufacturing technology in the event of a pandemic. I have been working on improving the manufacturing processes for Adenovirus vaccines to minimise the time required from concept to end product. I work closely with the Clinical Biomanufacturing facility to ensure all processes are transferable to a GMP environment.

Another aspect of my research is the design and development of new viral vectors.